Low discontinuation rates with Factive
Overall discontinuation rates due to AEs were 2.0% for Factive vs 2.1% for comparators.‡
* Randomized, double-blind, double-dummy, multicenter, parallel-group study with results from 60 medical centers in the US, United Kingdom, and Germany. A total of 360 adults (>40 years old) with ABECB were randomly assigned to receive gemifloxacin 320 mg QD/5 days or levofloxacin 500 mg QD/7 days. Treatment-related AEs occurred either during therapy or within 30 days post therapy.1
† Randomized, double-blind, multicenter, parallel-group study, conducted between November 2004 and April 2005, including 68 centers in 9 countries, including the US. Outpatients with mild to moderate CAP were randomized to receive gemifloxacin 320 mg QD for 5 or 7 days. Treatment-related AEs were assessed in 510 intent-to-treat patients and occurred either during therapy or within 30 days post therapy.2
‡ Comparator drugs include beta-lactam antibiotics, macrolides, or other fluoroquinolones.
Comparable adverse events profile to other antimicrobials
The most commonly reported adverse events with a frequency of ≥2% for patients receiving Factive 320 mg QD vs comparator drugs (beta-lactam antibiotics, macrolides, or other fluoroquinolones) are as follows: diarrhea, 5.0% vs 6.2%; rash, 3.5% vs 1.1%; nausea, 3.7% vs 4.5%; headache, 4.2% vs 5.2%; abdominal pain, 2.2% vs 2.2%; vomiting, 1.6% vs 2.0%; and dizziness, 1.7% vs 2.6%.
* Insufficient number of patients in this category for a meaningful analysis.
Powerful, once-daily convenience with Factive
Benefits of 5-day Factive
— Short 5-day therapy regimen with comparable efficacy to 7-day regimens in ABECB and mild to moderate CAP.1,2,4,5
— No significant drug-drug interactions seen with3:
— Warfarin (patients receiving concomitant warfarin should be monitored closely)
— Oral contraceptives
FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae.
*MDRSP: multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μ/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of FACTIVE and other antibacterial drugs, FACTIVE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
WARNING: Fluoroquinolones, including FACTIVE, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Fluoroquinolones, including FACTIVE, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid FACTIVE in patients with known history of myasthenia gravis.
Tendon rupture can occur during or after completion of therapy. FACTIVE should be discontinued if the patient experiences pain, swelling, inflammation, or rupture of a tendon.
FACTIVE is contraindicated in patients with a history of hypersensitivity to gemifloxacin, fluoroquinolone antibiotic agents, or any of the product components. Serious hypersensitivity and/or anaphylactic reactions have been reported in patients receiving fluoroquinolone therapy, including FACTIVE. Hypersensitivity reactions reported in patients receiving fluoroquinolone therapy have occasionally been fatal. These reactions may include serious, sometimes fatal skin reactions such as toxic epidermal necrolysis or Stevens-Johnson Syndrome; effects on the liver, including hepatitis, jaundice, and acute hepatic necrosis or failure; renal toxicities including interstitial nephritis and/or acute renal insufficiency or failure; and hematologic effects, including agranulocytosis, thrombocytopenia, and other hematologic abnormalities. These reactions may occur following the first dose or multiple doses. FACTIVE should be discontinued immediately at the first sign of an immediate type I hypersensitivity skin rash or any other manifestation of hypersensitivity reaction.
THE SAFETY AND EFFECTIVENESS OF FACTIVE IN CHILDREN, ADOLESCENTS (<18 YEARS OF AGE), PREGNANT WOMEN, AND LACTATING WOMEN HAVE NOT BEEN ESTABLISHED.
Fluoroquinolones may prolong the QT interval in some patients. FACTIVE should be avoided in patients with a history of prolongation of the QTc interval, patients with uncorrected electrolyte disorders (hypokalemia or hypomagnesemia), and patients receiving Class IA or Class III antiarrhythmic agents.
Rare cases of peripheral neuropathy have been reported in patients receiving quinolones.
In clinical studies with FACTIVE, central nervous system (CNS) effects have been reported infrequently. As with other fluoroquinolones, FACTIVE should be used with caution in patients with known or suspected CNS diseases. If CNS reactions occur, FACTIVE should be discontinued and appropriate measures instituted.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibiotic agents, including FACTIVE. If diarrhea occurs, evaluate for CDAD and treat appropriately.
In clinical trials, rash occurred more often with FACTIVE than therapy with comparator agents (2.7% vs. 0.6%). Increasing incidence of rash was associated with younger age (especially below 40), female gender, use of hormone replacement therapy, and longer duration of therapy.
Moderate to severe photosensitivity/phototoxicity reactions can be associated with the use of quinolones after sun or UV light exposure. Excessive exposure to the sun or UV light should be avoided.
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other cations, or Videx® (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE. Sucralfate should not be taken within 2 hours of FACTIVE.
In clinical trials, the most common adverse drug reactions (≥2%) were diarrhea, rash, nausea, headache, and abdominal pain.
To request a FACTIVE package insert, including the Medication Guide, please click here or call 1-888-661-9260 for a shipment.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
- 1 Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med. 2004;98:697.
- 2 File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia. A randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007;60:112-120.
- 3 Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis. 2005;41(suppl 2):S127-S135.
- 4 Factive (gemifloxacin mesylate) prescribing information, 2011. Cornerstone Therapeutics Inc.
- 5 File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C; and the 070 Clinical Study Group. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. J Chemother. 2000;12:314-325.